Data on 1,530 patients with rheumatoid arthritis (RA) in a real-life cohort from the CERERRA collaboration show that repeated cycles of rituximab provides clinical improvements. A significant (P < 0.0001) reduction in mean 28-joint disease activity score (DAS28) occurred between each round of retreatment, suggesting an improvement in disease. In a second analysis of 800 patients from the cohort, a fixed-interval treatment strategy was more effective than on-flare treatment, with the former yielding a lower average DAS28 (3.8 versus 4.6).